What is the 13F Pro Quality Score for NOTV?

13F Pro ranks Inotiv, Inc. (NOTV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NOTV's current score at https://13fpro.ai/research/NOTV (free sign-up required for the full ranking).

Which hedge funds own the most NOTV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NOTV include Orgel Wealth Management,, BANK OF AMERICA /DE/, LPL Financial. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NOTV as soon as new 13F filings post.

Where does 13F Pro source NOTV data?

All Inotiv, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inotiv, Inc. files with the SEC under CIK 720154. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NOTV in?

Inotiv, Inc. (NOTV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NOTV research updated on 13F Pro?

NOTV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inotiv, Inc.(NOTV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 720154 NOTV stock profile & AI dashboard →

13F Pro Quality Score

29.3/100

Rank #2,416 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

38.9/100

Profitability

19.7/100

Balance Sheet

15.6/100

Earnings Quality

30.0/100

Free Cash Flow

19.9/100

Institutional Flow

51.5/100

Revenue Scale

36.7/100

Dilution Risk

53.0/100

NOTV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Inotiv, Inc. (NOTV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NOTV at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,416 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (15.6) and profitability (19.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Inotiv, Inc. reports quarterly revenue of $117.7M, net income of $-32.5M, free cash flow of $-3.2M. Top institutional holders of NOTV by reported 13-F value include Orgel Wealth Management,, BANK OF AMERICA /DE/, LPL Financial, based on the most recent SEC filings. NOTV trades on the Nasdaq exchange and files with the SEC under CIK 720154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NOTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inotiv, Inc. directly from SEC EDGAR. Inotiv, Inc.'s 13F Pro composite quality score has ranged between 19 and 50 since 2021, currently 29.3 — a declining long-term trajectory across 29 quarterly and live scoring snapshots.

✦

Fun facts about Inotiv, Inc.

Quirks, history, and lore behind NOTV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Indiana.
2
The Numbers
Annual revenue in the range of a few hundred million dollars, built largely through acquisitions that roughly tripled its size in a short stretch — growth that came with a hefty debt load.
3
The History
Rooted in pharmaceutical research services dating back decades, the company rebranded and relisted as it pivoted from a niche university-affiliated lab into a full-service contract research organization.
4
The Secret
Its core business is running preclinical studies on behalf of drug developers — meaning it tests compounds in animals and lab settings so its clients don't have to build that infrastructure themselves.
5
The Lore
A splashy acquisition of Envigo dramatically expanded its research model supply operations, making it one of the larger providers of laboratory animals in North America — and drawing intense scrutiny from regulators and activists alike.
6
The Giveaway
This contract research and preclinical services company, trading under a four-letter ticker on Nasdaq, faced an FDA consent decree tied to its animal research facilities after the Envigo deal put it under a microscope.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$117.7M

Net Income

Q2 2026

$-32.5M

Free Cash Flow

Q2 2026

$-3.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.5% YoY

$513.0MFY 2025

FY21 $89.6MFY23 $572.4MFY24 $490.7MFY25 $513.0M

Net Income

+36.7% YoY

$-68.6MFY 2025

FY21 $10.9MFY23 $-105.1MFY24 $-108.4MFY25 $-68.6M

Operating Income

+64.2% YoY

$-30.9MFY 2025

FY21 $-5.6MFY23 $-81.5MFY24 $-86.4MFY25 $-30.9M

EPS (Diluted)

+49.6% YoY

$-2.11FY 2025

FY21 $0.19FY23 $-4.10FY24 $-4.19FY25 $-2.11

Total Assets

-1.3% YoY

$771.1MFY 2025

FY21 $321.9MFY23 $856.5MFY24 $781.4MFY25 $771.1M

Total Debt

+102.6% YoY

$804.2MFY 2025

FY21 $180.0MFY23 $385.7MFY24 $396.9MFY25 $804.2M

Op. Cash Flow

-53.6% YoY

$-10.5MFY 2025

FY21 $10.7MFY23 $27.9MFY24 $-6.8MFY25 $-10.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2018	FY 2017
Revenue	$513.0M +4.5%	$490.7M -14.3%	$572.4M +538.8%	$89.6M +240.1%	$26.3M +8.7%	$24.2M
Net Income	$-68.6M +36.7%	$-108.4M -3.1%	$-105.1M -1065.0%	$10.9M +5716.0%	$-194.0K -121.9%	$884.0K
Operating Income	$-30.9M +64.2%	$-86.4M -6.1%	$-81.5M -1350.0%	$-5.6M -40228.6%	$14.0K -98.9%	$1.3M
EPS (Diluted)	$-2.11 +49.6%	$-4.19 -2.2%	$-4.10 -2257.9%	$0.19 +1050.0%	$-0.02 -120.0%	$0.10
Total Assets	$771.1M -1.3%	$781.4M -8.8%	$856.5M +166.1%	$321.9M +929.3%	$31.3M +53.1%	$20.4M
Total Debt	$804.2M +102.6%	$396.9M +2.9%	$385.7M +114.3%	$180.0M +1610.3%	$10.5M +125.3%	$4.7M
Operating Cash Flow	$-10.5M -53.6%	$-6.8M -124.4%	$27.9M +159.5%	$10.7M +208.2%	$3.5M +182.1%	$1.2M

AI Insight: NOTV Financial Trends

Inotiv's debt has more than doubled to $821M while equity erodes to $77M, signaling acute balance-sheet distress despite modest revenue stability.

• Total debt surged from $399M in Q4 2024 to $821M in Q4 2025, then $821M in Q1 2026, reversing a prior deleveraging trend.

• Equity has collapsed from $182M in Q2 2024 to $77M in Q1 2026, an 58% erosion over eight quarters.

• Net losses widened to -$32M in Q1 2026, the steepest quarterly loss in the dataset, despite revenue of $118M.

• Revenue has remained rangebound between $106M and $138M across eight quarters, showing no meaningful growth trajectory.

⚠ Debt jumped ~$400M between Q2 2025 and Q3 2025; source and covenants of this new leverage are critical to monitor.

⚠ Operating cash flow turned positive at $14M in Q3 2025 but reverted to negative in Q4 2025 and Q1 2026 — sustainability is unproven.

⚠ Equity at $77M against $821M debt implies near-zero cushion; any asset impairment could push book value negative.

AI Insight: NOTV Ratio Trends

Inotiv's leverage has surged to a D/E of 10.65 in Q1 2026 while losses are deepening, reversing the modest mid-2025 improvement.

• Operating margin deteriorated sharply from -4.9% in Q3 2025 to -16.4% in Q1 2026, the worst quarterly reading in over a year.

• D/E ratio exploded from 2.35 in Q4 2024 to 10.65 in Q1 2026, signaling rapidly escalating balance-sheet stress.

• ROE collapsed to -168.4% in Q1 2026 from -25.1% in Q3 2025, reflecting both mounting losses and eroding equity base.

• A brief margin trough appeared to recover in Q1–Q3 2025, but Q4 2025 and Q1 2026 confirm the recovery has fully reversed.

⚠ D/E at 10.65 raises acute refinancing and covenant risk; any debt restructuring could further dilute equity holders.

⚠ ROIC of -8.6% in Q1 2026 versus -2.1% in Q1 2025 signals capital destruction is accelerating, not stabilizing.

⚠ Monitor whether Q2 2026 operating margin recovers toward the -4% range seen mid-2025, or continues the recent deterioration.

Get alerted when NOTV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inotiv, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NOTV

Orgel Wealth Management, LLC
$129.6M7,045,871 sh
BANK OF AMERICA CORP /DE/
$97.6M5,305,892 sh
LPL Financial LLC
$66.4M3,610,103 sh
Global X Japan Co., Ltd.
$62.9M3,418,081 sh
MORGAN STANLEY
$52.7M2,861,716 sh
WELLS FARGO & COMPANY/MN
$47.1M2,560,241 sh
ENVESTNET ASSET MANAGEMENT INC
$41.4M2,249,640 sh
Lido Advisors, LLC
$30.2M1,642,883 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$29.1M1,582,717 sh
FUKOKU MUTUAL LIFE INSURANCE Co
$28.5M1,551,000 sh

Fund	Value	Shares
Orgel Wealth Management, LLC	$129.6M	7,045,871
BANK OF AMERICA CORP /DE/	$97.6M	5,305,892
LPL Financial LLC	$66.4M	3,610,103
Global X Japan Co., Ltd.	$62.9M	3,418,081
MORGAN STANLEY	$52.7M	2,861,716
WELLS FARGO & COMPANY/MN	$47.1M	2,560,241
ENVESTNET ASSET MANAGEMENT INC	$41.4M	2,249,640
Lido Advisors, LLC	$30.2M	1,642,883
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$29.1M	1,582,717
FUKOKU MUTUAL LIFE INSURANCE Co	$28.5M	1,551,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NOTV on your watchlist

Track score changes the day Inotiv, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NOTV a good stock to buy?

13F Pro's AI-powered analysis of Inotiv, Inc. (NOTV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NOTV are available on the NOTV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NOTV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NOTV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inotiv, Inc.'s investment landscape.